CASI Pharmaceuticals jumps as partner BioInvent's lymphoma treatment gets orphan drug tag
20/01/2022 13:08
** Biopharma co CASI.O shares rise as much as 18.8% to 82
cents premarket
** Says U.S. health regulator granted orphan drug
designation to partner BioInvent's lead drug, BI-1206
urn:newsml:reuters.com:*:nPn3gQ89Na
** BI-1206 being tested in two early-stage trials as
potential treatment for follicular lymphoma, cancer of lymph
system
** Co, BioInvent entered into licensing agreement in 2020
for development of BI-1206 in mainland China, Taiwan, Hong Kong
and Macau (https://bit.ly/3GLk16t)
** CASI fell ~73% in 2021
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))